Company
Amicus Therapeutics (FOLD)
Redefining Expectations in Rare Disease
Also known as Amicus, Amicus Therapeutics, Inc
- Status
- Acquiredas of 2026-09-20Source (opens in a new tab)
- Legal name
- Amicus Therapeutics, Inc
Claim, correct or request removal
Record updated 29 September 2026
About
Amicus is a wholly owned subsidiary of BioMarin Pharmaceutical Inc., a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions.
Funding snapshot
- Total raised
- $314MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $30M2023-10-05
Funding rounds
- Round, 2023
- $30M2023-10-05, SEC form D sold, 2 investors
- Round, 2021
- $200M2021-09-29, SEC form D sold, 9 investors
- Round, 2016
- $4.7M2016-07-05, SEC form D sold, 18 investors
- Round, 2013
- $15M2013-11-20, SEC form D sold, 5 investors
- Round, 2013
- $15M2013-11-19, SEC form D sold, 29 investors
- Round, 2012
- $18.6M2012-07-17, SEC form D sold, 1 investor
- Round, 2010
- $31.3M2010-10-28, SEC form D sold, 1 investor
About the company
- Status notes
- Amicus is a wholly owned subsidiary of BioMarin Pharmaceutical Inc.
Loading relationship preview